Phase III Trial Evaluates Quizartinib for FLT3-ITD–Positive AML
Posted: 08/01/2022 | By: Chase Doyle

Data was presented during the Presidential Symposium at the European Hematology Association (EHA) 2022 Congress on a new treatment option for a difficult-to-treat subset of patients with acute myeloid leukemia (AML).

Question 1 of 5

What was the cumulative incidence of relapse at 24 months among patients treated with quizartinib?

Choose 1